;PMID: 9756946
;source_file_1779.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..120] = [t:47..120]
;2)sentence:[e:122..164] = [t:122..164]
;3)section:[e:168..187] = [t:168..187]
;4)section:[e:191..289] = [t:191..289]
;5)sentence:[e:293..396] = [t:293..396]
;6)sentence:[e:397..522] = [t:397..522]
;7)sentence:[e:524..702] = [t:524..702]
;8)sentence:[e:703..841] = [t:703..841]
;9)sentence:[e:842..966] = [t:842..966]
;10)sentence:[e:967..1040] = [t:967..1040]
;11)sentence:[e:1041..1225] = [t:1041..1225]
;12)sentence:[e:1226..1368] = [t:1226..1368]
;13)sentence:[e:1370..1452] = [t:1370..1452]
;14)sentence:[e:1453..1556] = [t:1453..1556]
;15)sentence:[e:1557..1617] = [t:1557..1617]
;16)sentence:[e:1618..1699] = [t:1618..1699]
;17)section:[e:1703..1747] = [t:1703..1747]

;section 0 Span:0..41
;J Biol Chem. 1998 Oct 9;273(41):26969-76.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[13..17] 1998) (NNP:[18..21] Oct) (CD:[22..27] 9;273)
        (-LRB-:[27..28] -LRB-) (CD:[28..30] 41) (-RRB-:[30..31] -RRB-)
        (::[31..32] :) (CD:[32..37] 26969) (::[37..38] -) (CD:[38..40] 76)
        (.:[40..41] .)))

;sentence 1 Span:47..120
;Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress.
;[66..85]:cyp450:"cytochrome P450 1A1"
;[91..99]:substance:"promoter"
(SENT
  (NP-HLN
    (NP (RP:[47..51] Down) (HYPH:[51..52] -) (NN:[52..62] regulation))
    (PP (IN:[63..65] of)
      (NP
        (NML
          (NML (NN:[66..76] cytochrome) (NN:[77..81] P450))
          (NN:[82..85] 1A1))
        (NN:[86..90] gene) (NN:[91..99] promoter)))
    (PP (IN:[100..102] by)
      (NP (JJ:[103..112] oxidative) (NN:[113..119] stress)))
    (.:[119..120] .)))

;sentence 2 Span:122..164
;Critical contribution of nuclear factor 1.
;[147..163]:substance:"nuclear factor 1"
(SENT
  (NP-HLN
    (NP (JJ:[122..130] Critical) (NN:[131..143] contribution))
    (PP (IN:[144..146] of)
      (NP (JJ:[147..154] nuclear) (NN:[155..161] factor) (CD:[162..163] 1)))
    (.:[163..164] .)))

;section 3 Span:168..187
;Morel Y, Barouki R.
(SEC
  (FRAG (NNP:[168..173] Morel) (NNP:[174..175] Y) (,:[175..176] ,)
        (NNP:[177..184] Barouki) (NNP:[185..187] R.)))

;section 4 Span:191..289
;INSERM U490, Centre Universitaire des Saints-Peres, 45 rue des Saints-Peres, 
;75006 Paris, France.
(SEC
  (FRAG (NNP:[191..197] INSERM) (CD:[198..202] U490) (,:[202..203] ,)
        (NNP:[204..210] Centre) (NNP:[211..224] Universitaire)
        (NNP:[225..228] des) (NNP:[229..235] Saints) (HYPH:[235..236] -)
        (NNP:[236..241] Peres) (,:[241..242] ,) (CD:[243..245] 45)
        (NNS:[246..249] rue) (VBZ:[250..253] des) (NNP:[254..260] Saints)
        (HYPH:[260..261] -) (NNP:[261..266] Peres) (,:[266..267] ,)
        (CD:[269..274] 75006) (NNP:[275..280] Paris) (,:[280..281] ,)
        (NNP:[282..288] France) (.:[288..289] .)))

;sentence 5 Span:293..396
;Oxidative stress interferes with several cellular functions, in particular 
;transcriptional regulation.
(SENT
  (S
    (NP-SBJ (JJ:[293..302] Oxidative) (NN:[303..309] stress))
    (VP (VBZ:[310..320] interferes)
      (PP-CLR (IN:[321..325] with)
        (NP
          (NP (JJ:[326..333] several) (JJ:[334..342] cellular)
              (NNS:[343..352] functions))
          (,:[352..353] ,)
          (PP (IN:[354..356] in)
            (PP (JJ:[357..367] particular)
              (NP (JJ:[369..384] transcriptional) (NN:[385..395] regulation)))))))
    (.:[395..396] .)))

;sentence 6 Span:397..522
;We show here that the human cytochrome P450 1A1  (CYP1A1) is down-regulated
;at the transcriptional level by oxidative stress.
;[425..444]:cyp450:"cytochrome P450 1A1"
;[447..453]:cyp450:"CYP1A1"
(SENT
  (S
    (NP-SBJ (PRP:[397..399] We))
    (VP (VBP:[400..404] show)
      (ADVP (RB:[405..409] here))
      (SBAR (IN:[410..414] that)
        (S
          (NP-SBJ-1
            (NP (DT:[415..418] the) (JJ:[419..424] human)
               (NN:[425..435] cytochrome) (NN:[436..440] P450)
               (NN:[441..444] 1A1))
            (NP (-LRB-:[446..447] -LRB-) (NN:[447..453] CYP1A1)
                (-RRB-:[453..454] -RRB-)))
          (VP (VBZ:[455..457] is)
            (VP (RP:[458..462] down) (HYPH:[462..463] -)
                (VBN:[463..472] regulated)
              (NP-1 (-NONE-:[472..472] *))
              (PP-LOC (IN:[473..475] at)
                (NP (DT:[476..479] the) (JJ:[480..495] transcriptional)
                    (NN:[496..501] level)))
              (PP (IN:[502..504] by)
                (NP-LGS (JJ:[505..514] oxidative) (NN:[515..521] stress))))))))
    (.:[521..522] .)))

;sentence 7 Span:524..702
;Basal as well as 2,3,7, 8-tetrachloro-p-dioxin-induced promoter activities
;are  strongly impaired by H2O2 treatment or glutathione depletion with 
;L-buthionine-(S,R)-sulfoximine.
;[541..570]:substance:"2,3,7, 8-tetrachloro-p-dioxin"
;[579..587]:substance:"promoter"
;[625..629]:substance:"H2O2"
;[643..654]:substance:"glutathione"
;[671..701]:substance:"L-buthionine-(S,R)-sulfoximine"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[524..529] Basal)
        (NML-1 (-NONE-:[529..529] *P*)))
      (CONJP (RB:[530..532] as) (RB:[533..537] well) (IN:[538..540] as))
      (NP
        (ADJP
           (NN:[541..547] 2,3,7,) (NN:[548..570] 8-tetrachloro-p-dioxin)
          (HYPH:[570..571] -) (VBN:[571..578] induced))
        (NML-1 (NN:[579..587] promoter) (NNS:[588..598] activities))))
    (VP (VBP:[599..602] are)
      (ADVP-MNR (RB:[604..612] strongly))
      (VP (VBN:[613..621] impaired)
        (NP-2 (-NONE-:[621..621] *))
        (PP (IN:[622..624] by)
          (NP-LGS
            (NP (NN:[625..629] H2O2) (NN:[630..639] treatment))
            (CC:[640..642] or)
            (NP
              (NP (NN:[643..654] glutathione) (NN:[655..664] depletion))
              (PP (IN:[665..669] with)
                (NP (NN:[671..701] L-buthionine--LRB-S,R-RRB--sulfoximine))))))))
    (.:[701..702] .)))

;sentence 8 Span:703..841
;Tumor necrosis factor alpha inhibits CYP1A1  expression, and this inhibition
;is prevented by the antioxidant pyrrolidine  dithiocarbamate.
;[703..730]:substance:"Tumor necrosis factor alpha"
;[740..746]:cyp450:"CYP1A1"
;[800..811]:substance:"antioxidant"
;[812..840]:substance:"pyrrolidine  dithiocarbamate"
(SENT
  (S
    (S
      (NP-SBJ (NN:[703..708] Tumor) (NN:[709..717] necrosis)
              (NN:[718..724] factor) (SYM:[725..730] alpha))
      (VP (VBZ:[731..739] inhibits)
        (NP (NN:[740..746] CYP1A1) (NN:[748..758] expression))))
    (,:[758..759] ,) (CC:[760..763] and)
    (S
      (NP-SBJ-1 (DT:[764..768] this) (NN:[769..779] inhibition))
      (VP (VBZ:[780..782] is)
        (VP (VBN:[783..792] prevented)
          (NP-1 (-NONE-:[792..792] *))
          (PP (IN:[793..795] by)
            (NP-LGS
              (NP (DT:[796..799] the) (JJ:[800..811] antioxidant))
              (NP (NN:[812..823] pyrrolidine) (NN:[825..840] dithiocarbamate)))))))
    (.:[840..841] .)))

;sentence 9 Span:842..966
;We show that these regulations depend on the integrity of the  nuclear factor
;1 (NFI) site located in the proximal promoter.
;[923..926]:substance:"NFI"
;[957..965]:substance:"promoter"
(SENT
  (S
    (NP-SBJ (PRP:[842..844] We))
    (VP (VBP:[845..849] show)
      (SBAR (IN:[850..854] that)
        (S
          (NP-SBJ (DT:[855..860] these) (NNS:[861..872] regulations))
          (VP (VBP:[873..879] depend)
            (PP-CLR (IN:[880..882] on)
              (NP
                (NP (DT:[883..886] the) (NN:[887..896] integrity))
                (PP (IN:[897..899] of)
                  (NP
                    (NP
                      (NML
                        (NML (DT:[900..903] the) (JJ:[905..912] nuclear)
                             (NN:[913..919] factor) (CD:[920..921] 1))
                        (NML (-LRB-:[922..923] -LRB-) (NN:[923..926] NFI)
                             (-RRB-:[926..927] -RRB-)))
                      (NN:[928..932] site))
                    (VP (VBN:[933..940] located)
                      (NP (-NONE-:[940..940] *))
                      (PP-LOC (IN:[941..943] in)
                        (NP (DT:[944..947] the) (JJ:[948..956] proximal)
                            (NN:[957..965] promoter))))))))))))
    (.:[965..966] .)))

;sentence 10 Span:967..1040
;We therefore  examined the redox regulation of this transcription factor.
;[1019..1039]:substance:"transcription factor"
(SENT
  (S
    (NP-SBJ (PRP:[967..969] We))
    (ADVP (RB:[970..979] therefore))
    (VP (VBD:[981..989] examined)
      (NP
        (NP (DT:[990..993] the) (NN:[994..999] redox)
            (NN:[1000..1010] regulation))
        (PP (IN:[1011..1013] of)
          (NP (DT:[1014..1018] this)
             (NN:[1019..1032] transcription) (NN:[1033..1039] factor)))))
    (.:[1039..1040] .)))

;sentence 11 Span:1041..1225
;Treatment of human  HepG2 or rat H4 hepatoma cells with H2O2 or
;L-buthionine-(S, R)-sulfoximine  inactivates the binding of the NFI
;transcription factor to its DNA consensus  sequence.
;[1097..1101]:substance:"H2O2"
;[1105..1136]:substance:"L-buthionine-(S, R)-sulfoximine"
;[1169..1193]:substance:"NFI transcription factor"
;[1201..1204]:substance:"DNA"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1041..1050] Treatment))
      (PP (IN:[1051..1053] of)
        (NP
          (NP (JJ:[1054..1059] human) (NN:[1061..1066] HepG2))
          (CC:[1067..1069] or)
          (NP (NN:[1070..1073] rat) (NN:[1074..1076] H4)
              (NN:[1077..1085] hepatoma) (NNS:[1086..1091] cells))))
      (PP (IN:[1092..1096] with)
        (NP
          (NP (NN:[1097..1101] H2O2))
          (CC:[1102..1104] or)
          (NP (NN:[1105..1121] L-buthionine--LRB-S,)
              (NN:[1122..1136] R-RRB--sulfoximine)))))
    (VP (VBZ:[1138..1149] inactivates)
      (NP
        (NP (DT:[1150..1153] the) (NN:[1154..1161] binding))
        (PP (IN:[1162..1164] of)
          (NP (DT:[1165..1168] the)
             (NN:[1169..1172] NFI) (NN:[1173..1186] transcription)
             (NN:[1187..1193] factor)))
        (PP (TO:[1194..1196] to)
          (NP (PRP$:[1197..1200] its) (NN:[1201..1204] DNA)
              (NN:[1205..1214] consensus) (NN:[1216..1224] sequence)))))
    (.:[1224..1225] .)))

;sentence 12 Span:1226..1368
;Furthermore, H2O2 treatment leads to a dose-dependent decrease of  reporter
;gene expressions driven by promoters containing NFI binding sites.
;[1239..1243]:substance:"H2O2"
;[1329..1338]:substance:"promoters"
;[1350..1353]:substance:"NFI"
(SENT
  (S
    (ADVP (RB:[1226..1237] Furthermore))
    (,:[1237..1238] ,)
    (NP-SBJ (NN:[1239..1243] H2O2) (NN:[1244..1253] treatment))
    (VP (VBZ:[1254..1259] leads)
      (PP-CLR (TO:[1260..1262] to)
        (NP
          (NP (DT:[1263..1264] a)
            (ADJP (NN:[1265..1269] dose) (HYPH:[1269..1270] -)
                  (JJ:[1270..1279] dependent))
            (NN:[1280..1288] decrease))
          (PP (IN:[1289..1291] of)
            (NP
              (NP
                (NML (NN:[1293..1301] reporter) (NN:[1302..1306] gene))
                (NNS:[1307..1318] expressions))
              (VP (VBN:[1319..1325] driven)
                (NP (-NONE-:[1325..1325] *))
                (PP (IN:[1326..1328] by)
                  (NP-LGS
                    (NP (NNS:[1329..1338] promoters))
                    (VP (VBG:[1339..1349] containing)
                      (NP (NN:[1350..1353] NFI) (NN:[1354..1361] binding)
                          (NNS:[1362..1367] sites)))))))))))
    (.:[1367..1368] .)))

;sentence 13 Span:1370..1452
;Glutathione depletion and catalase inhibition also repress a NFI-driven 
;promoter.
;[1370..1381]:substance:"Glutathione"
;[1396..1404]:substance:"catalase"
;[1431..1434]:substance:"NFI"
;[1443..1451]:substance:"promoter"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1370..1381] Glutathione) (NN:[1382..1391] depletion))
      (CC:[1392..1395] and)
      (NP (NN:[1396..1404] catalase) (NN:[1405..1415] inhibition)))
    (ADVP (RB:[1416..1420] also))
    (VP (VBP:[1421..1428] repress)
      (NP (DT:[1429..1430] a)
        (ADJP (NN:[1431..1434] NFI) (HYPH:[1434..1435] -)
              (VBN:[1435..1441] driven))
        (NN:[1443..1451] promoter)))
    (.:[1451..1452] .)))

;sentence 14 Span:1453..1556
;Under the same conditions, the CP-1 transcription factor activity is  not
;affected by oxidative stress.
;[1484..1509]:substance:"CP-1 transcription factor"
(SENT
  (S
    (PP (IN:[1453..1458] Under)
      (NP (DT:[1459..1462] the) (JJ:[1463..1467] same)
          (NNS:[1468..1478] conditions)))
    (,:[1478..1479] ,)
    (NP-SBJ-2 (DT:[1480..1483] the)
      (NML (NN:[1484..1488] CP-1) (NN:[1489..1502] transcription)
           (NN:[1503..1509] factor))
      (NN:[1510..1518] activity))
    (VP (VBZ:[1519..1521] is) (RB:[1523..1526] not)
      (VP (VBN:[1527..1535] affected)
        (NP-2 (-NONE-:[1535..1535] *))
        (PP (IN:[1536..1538] by)
          (NP-LGS (JJ:[1539..1548] oxidative) (NN:[1549..1555] stress)))))
    (.:[1555..1556] .)))

;sentence 15 Span:1557..1617
;Thus, NFI seems particularly sensitive to  oxidative stress.
;[1563..1566]:substance:"NFI"
(SENT
  (S
    (ADVP (RB:[1557..1561] Thus))
    (,:[1561..1562] ,)
    (NP-SBJ (NN:[1563..1566] NFI))
    (VP (VBZ:[1567..1572] seems)
      (ADJP-PRD (RB:[1573..1585] particularly) (JJ:[1586..1595] sensitive)
        (PP (TO:[1596..1598] to)
          (NP (JJ:[1600..1609] oxidative) (NN:[1610..1616] stress)))))
    (.:[1616..1617] .)))

;sentence 16 Span:1618..1699
;This accounts, at least partially, for the regulation of  cyp1A1 gene
;expression.
;[1676..1682]:cyp450:"cyp1A1"
(SENT
  (S
    (NP-SBJ (DT:[1618..1622] This))
    (VP (VBZ:[1623..1631] accounts) (,:[1631..1632] ,)
      (ADVP (IN:[1633..1635] at) (RBS:[1636..1641] least)
            (RB:[1642..1651] partially))
      (,:[1651..1652] ,)
      (PP-CLR (IN:[1653..1656] for)
        (NP
          (NP (DT:[1657..1660] the) (NN:[1661..1671] regulation))
          (PP (IN:[1672..1674] of)
            (NP (NN:[1676..1682] cyp1A1) (NN:[1683..1687] gene)
                (NN:[1688..1698] expression))))))
    (.:[1698..1699] .)))

;section 17 Span:1703..1747
;PMID: 9756946 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1703..1707] PMID) (::[1707..1708] :) (CD:[1709..1716] 9756946)
        (NN:[1717..1718] -LSB-) (NNP:[1718..1724] PubMed) (::[1725..1726] -)
        (NN:[1727..1734] indexed) (IN:[1735..1738] for)
        (NNP:[1739..1747] MEDLINE-RSB-)))
